Management of bone loss after organ transplantation

被引:60
作者
Cohen, A
Sambrook, P
Shane, E
机构
[1] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[2] Duke Univ, Dept Med, Durham, NC USA
[3] Univ Sydney, Inst Bone & Joint Res, Sydney, NSW 2006, Australia
关键词
D O I
10.1359/JBMR.040912
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Organ transplant recipients experience rapid bone loss and high fracture rates, particularly during the early post-transplant period. Early rapid bone loss occurs in the setting of uncoupled bone turnover with increased bone resorption and decreased bone formation. Because there are no clinical factors that reliably predict post-transplant bone loss and fractures in the individual patient, all transplant recipients should be considered candidates for early preventive therapy for osteoporosis. Long-term transplant recipients with densitometric osteoporosis and/or fractures should also receive treatment. Although active metabolites of vitamin D and bisphosphonates have both shown efficacy, data from clinical trials suggest that bisphosphonates are the safest and most consistently effective agents for the prevention and treatment of post-transplantation osteoporosis in adults. Kidney transplant recipients represent a special population, and more research is needed to delineate the risks and benefits of treating bone disease in these patients.
引用
收藏
页码:1919 / 1932
页数:14
相关论文
共 72 条
[21]  
Fahrleitner A, 2002, J BONE MINER RES, V17, pS388
[22]   Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation [J].
Fan, SLS ;
Kumar, S ;
Cunningham, J .
KIDNEY INTERNATIONAL, 2003, 63 (06) :2275-2279
[23]   Pamidronate therapy as prevention of bone loss following renal transplantation [J].
Fan, SLS ;
Almond, MK ;
Ball, E ;
Evans, K ;
Cunningham, J .
KIDNEY INTERNATIONAL, 2000, 57 (02) :684-690
[24]   Bone metabolism and gonad function in male patients undergoing liver transplantation: A two-year longitudinal study [J].
Floreani, A ;
Mega, A ;
Tizian, L ;
Burra, P ;
Boccagni, P ;
Baldo, V ;
Fagiuoli, S ;
Naccarato, R ;
Luisetto, G .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (09) :749-754
[25]   Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation [J].
GarciaDelgado, I ;
Prieto, S ;
GilFraguas, L ;
Robles, E ;
Rufilanchas, JJ ;
Hawkins, F .
CALCIFIED TISSUE INTERNATIONAL, 1997, 60 (02) :155-159
[26]   Alendronate prevents further bone loss in renal transplant recipients [J].
Giannini, S ;
D'Angelo, A ;
Carraro, G ;
Nobile, M ;
Rigotti, P ;
Bonfante, L ;
Marchini, F ;
Zaninotto, M ;
Carbonare, LD ;
Sartori, L ;
Crepaldi, G .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (11) :2111-2117
[27]  
Goodman WG, 2003, PRIMER METABOLIC BON, P430
[28]  
Grotz W, 2001, J AM SOC NEPHROL, V12, P1530, DOI 10.1681/ASN.V1271530
[29]   Treatment of osteopenia and osteoporosis after kidney transplantation [J].
Grotz, WH ;
Rump, LC ;
Niessen, A ;
Schmidt-Gayk, H ;
Reichelt, A ;
Kirste, G ;
Olschewski, M ;
Schollmeyer, PJ .
TRANSPLANTATION, 1998, 66 (08) :1004-1008
[30]   Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation [J].
Haas, M ;
Leko-Mohr, Z ;
Roschger, P ;
Kletzmayr, J ;
Schwarz, C ;
Mitterbauer, C ;
Steininger, R ;
Grampp, S ;
Klaushofer, K ;
Delling, G ;
Oberbauer, R .
KIDNEY INTERNATIONAL, 2003, 63 (03) :1130-1136